CRISPR Therapeutics Stock Falls 3.5% on Q3 Results

CRISPR Therapeutics (NASDAQ: CRSP) disappointed the market today with its third-quarter results, due in no small part to a dramatic but expected flip into the red on the bottom line.

For the quarter, the company's collaboration revenue withered to roughly $148,000, from the year-ago figure of nearly $212 million. The extreme fall was due to the fact that in the year-ago quarter, the clinical-stage company received development funds from longtime partner Vertex that comprised the vast bulk of its revenue.

Image source: Getty Images.

Continue reading

Source Fool.com